The results indicated that ASCC3 expression had no impact on the OS of patients with esophageal carcinoma (ESCA), stomach adenocarcinoma (STAD), colon adenocarcinoma (COAD), liver hepatocellular carcinoma (LIHC), cholangiocarcinoma (CHOL) and pancreatic adenocarcinoma (PAAD). This evidence concerns the gene ASCC3 and cholangiocarcinoma.